These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27091119)

  • 1. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
    Ungar B; Mazor Y; Weisshof R; Yanai H; Ron Y; Goren I; Waizbard A; Yavzori M; Fudim E; Picard O; Loebstein R; Kopylov U; Dotan I; Chowers Y; Eliakim R; Ben-Horin S
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1293-9. PubMed ID: 27091119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab.
    Croft A; Walsh A; Doecke J; Cooley R; Howlett M; Radford-Smith G
    Aliment Pharmacol Ther; 2013 Aug; 38(3):294-302. PubMed ID: 23786158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
    Brandse JF; Mathôt RA; van der Kleij D; Rispens T; Ashruf Y; Jansen JM; Rietdijk S; Löwenberg M; Ponsioen CY; Singh S; van den Brink GR; D'Haens GR
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):251-8.e1-2. PubMed ID: 26545802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.
    Choy MC; Seah D; Faleck DM; Shah SC; Chao CY; An YK; Radford-Smith G; Bessissow T; Dubinsky MC; Ford AC; Churilov L; Yeomans ND; De Cruz PP
    Inflamm Bowel Dis; 2019 Jun; 25(7):1169-1186. PubMed ID: 30605549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Bar-Yoseph H; Levhar N; Selinger L; Manor U; Yavzori M; Picard O; Fudim E; Kopylov U; Eliakim R; Ben-Horin S; Chowers Y; Ungar B
    Aliment Pharmacol Ther; 2018 Jan; 47(2):212-218. PubMed ID: 29124774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
    BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
    Aliment Pharmacol Ther; 2018 Feb; 47(4):478-484. PubMed ID: 29210094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
    Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
    Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
    Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
    J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis.
    Sebastian S; Myers S; Argyriou K; Martin G; Los L; Fiske J; Ranjan R; Cooper B; Goodoory V; Ching HL; Jayasooriya N; Brooks J; Dhar A; Shenoy AH; Limdi JK; Butterworth J; Allen PB; Samuel S; Moran GW; Shenderey R; Parkes G; Lobo A; Kennedy NA; Subramanian S; Raine T
    Aliment Pharmacol Ther; 2019 Sep; 50(6):675-683. PubMed ID: 31456297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
    Thukral C; Cheifetz A; Peppercorn MA
    Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids.
    Llaó J; Naves JE; Ruiz-Cerulla A; Marín L; Mañosa M; Rodríguez-Alonso L; Cabré E; Garcia-Planella E; Guardiola J; Domènech E
    J Crohns Colitis; 2014 Nov; 8(11):1523-8. PubMed ID: 25066954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.
    Chaparro M; Burgueño P; Iglesias E; Panés J; Muñoz F; Bastida G; Castro L; Jiménez C; Mendoza JL; Barreiro-de Acosta M; Senent SG; Gomollón F; Calvet X; García-Planella E; Gómez M; Hernández V; Hinojosa J; Mañosa M; Nyssen OP; Gisbert JP
    Aliment Pharmacol Ther; 2012 Jan; 35(2):275-83. PubMed ID: 22142227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
    Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.